RxDoctor Payments Data

Patrick Sullivan, PA

Physician Assistant · Brockton, MANPI 1972024594

Payments from drug & device makers

$2,795in general payments, 2019–2025

Across 137 payments — averaging $20.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$841
  • Lilly USA, LLC$490
  • Abbott$299
  • Sanofi-aventis U.S. LLC$212
  • Amgen$188
  • AstraZeneca$163
  • plus $602 from 7 others

What the payments were for

  • Food & beverage$2,58592%
  • Education$1004%
  • Other$1104%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,795 in reported general payments places this provider in the 90th percentile of 3,507 physician assistant providers in Massachusetts.

See all physician assistant providers in Massachusetts

Medicare billing

Part B allowed, 2024
$75,424
Medicare patients
303
Services billed
1,204

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide458$602,894
TrulicityDulaglutide395$537,873
MounjaroTirzepatide280$339,277
JardianceEmpagliflozin248$316,563
Humulin R U-500 KwikpenInsulin Regular, Human83$143,381
JanuviaSitagliptin Phosphate68$87,032
Tresiba Flextouch U-100Insulin Degludec109$70,954
Tresiba Flextouch U-200Insulin Degludec80$65,426
FarxigaDapagliflozin Propanediol59$61,832
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog54$49,574
TradjentaLinagliptin33$49,109
Fiasp FlextouchInsulin Aspart (Niacinamide)45$47,091
RybelsusSemaglutide36$38,771
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/731$31,821
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog57$29,499

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Baqsimi$490$886,249691 claims
Novo NordiskOzempic, Rybelsus, Novolog$841$645,720509 claims
MerckJanuvia$108$87,03268 claims
AstraZenecaFarxiga$163$61,83259 claims
Sanofi-aventis U.S. LLCLantus$212$1,97813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,507 physician assistant providers in Massachusetts.

Other physician assistant in Brockton

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →